Trials / Completed
CompletedNCT05429320
A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)
A Phase II Adaptive Study of Local Ablative Therapy (LAT) for Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Using Minimal Residual Disease (MRD) as an Integral Biomarker
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see whether receiving local ablative therapy (LAT) when minimal residual disease/MRD levels are rising can reduce MRD levels and control metastatic non-small cell lung cancer/NSCLC longer compared to systemic therapy.
Conditions
- Non-small Cell Lung Cancer
- Metastatic Non Small Cell Lung Cancer
- Nsclc
- NSCLC Stage IV
- Minimal Residual Disease
- Non Small Cell Lung Cancer Metastatic
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Local ablative therapy | In part I, 33 patients with metastatic NSCLC with: a) NR-VAF but b) without radiographic progression of disease, will be treated with LAT. In Part II of the study, patients will be randomized to standard of care (continuation of systemic therapy) vs. LAT to all sites of disease |
| OTHER | Blood collection to assess for ctDNA | Participants will undergo ctDNA collection in conjunction with their standard of care therapy. |
Timeline
- Start date
- 2022-06-15
- Primary completion
- 2026-01-28
- Completion
- 2026-01-28
- First posted
- 2022-06-23
- Last updated
- 2026-02-02
Locations
9 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT05429320. Inclusion in this directory is not an endorsement.